Glaucoma Risk May Be Underdiagnosed in Patients with Retinal Vein Occlusions
However, data show RVO patients with clinical findings associated with glaucoma risk are often not coded with suspected glaucoma.
Predictive AI Model Identifies nAMD Treatment Response Biomarkers
A new assessment from ARVO 2022 showed methodology to predict one-year treatment response to treat-and-extend ranibizumab at 1 year.
Semaglutide Not Associated with Worsening of Diabetic Retinopathy Progression
The study agent was otherwise not associated with an increased number of intravitreal injections over a 12-month period.
Progression in Complement Inhibitors, Retina Gene Therapies
Veeral S. Sheth, MD, MBA, discusses promising agents in development for geographic atrophy and other under-addressed ophthalmic diseases.
Diabetic Retinopathy May Require Greater Interval Between Anti-VEGF Treatments
Patients with DR had an average interval between anti-VEGF injections of 70 days, compared to 54 days for RVO patients and 55 days for wetAMD patients.
How Omega-3 Fatty Acids May Fit Into Future Ophthalmic Care Recommendations
One researcher suggests the supplement may serve as an add-on measurement against AMD progression in early-stage patients.
What Fish Oil Supplements May Provide to Retina Disease Management
An ARVO 2022 study author discusses her team's research into omega-3 fatty acids for diseases including dry AMD.
Pilocarpine Ophthalmic Solution Linked to Sustained Improvements in Intermediate VA
The estimated median duration of ≥1 line gained was greater than 9 hours on both study day 1 and day 30 in patients with presbyopia treated with the study agent.
Lone Brolucizumab Linked to Fewer Injections Than Alternating Anti-VEGFs
A new cohort analysis suggest one-year intravitreal treatment burden can be significantly reduced when patients are only administered brolucizumab.
Small Proportion of Patients with MEfCRVO Showed Poor Response After Aflibercept
Data suggest baseline vision was a key predictor of poor response at Week 24 in patients with macular edema secondary to central retinal vein occlusion.
Dopamine Treatment May Delay Onset of Diabetic Retinopathy
New research found veterans with diabetes who took L-DOPA and dopamine agonists showed delayed onset of vascular pathology associated with DR.
Intravitreal Steroids, Anti-VEGF Combination May Resolve Resistant Wet AMD
A new contribution of data evidences the "controversial" use of concomitant steroids in patients who do not benefit from monotherapy anti-VEGF.
Omega-3 Fatty Acid Supplements Linked to Improved Vision, Quality of Life in Dry AMD Patients
A new study shows BCVA scores and blood levels of AA/EPA significantly improved in treated patients with dry AMD or Stargardt disease at 24 weeks.
Port Delivery System Release Is Predictable, Tailorable for nAMD Treatment
An investigation into the diffusion, capacity and drug concentrations showed predictable flexibility with the novel ophthalmic implant device.
Disparities Observed in Diabetic Retinopathy Rates By Gender, Ethnicity
Data show Black individuals had a 1.41 times higher odds of having type 2 diabetic retinopathy when compared to white individuals.
Diabetic Vision Loss Care Lacks Specialty Collaborations
Research at ARVO 2021 highlighted a gamut of interplaying diabetes and vision loss risk factors, and even treatments for both. But experts depict a referral and care process that lacks whole diabetes care.
Gene Therapy AGTC-501 Hits Phase 1/2 Marks for Rare Pediatric Blindness
A podcast interview with study author Paul Yang, MD, PhD, on the current research and future implementation of the agent.
Brolucizumab Comparable to Aflibercept for DME
Data from the KITE study shows that ≥50% of brolucizumab patients maintained a 12-week interval schedule through 52 weeks.
Telehealth Could Be Feasible Alternative in Ophthalmology
Patients who utilized virtual and in-person visits had comparable numbers of follow-ups, referrals, and outpatient surgeries.
Fluticasone Acetate Implant May Improve Retinal Vein Occlusion Macular Edema
The implant was linked to visual acuity improvements at final follow-up visit.
Yearly Dosing of AXT107 May Have Promise for Retinal Diseases
Animal models suggest the investigative treatment is safe and tolerable in treating retinal vascular diseases.
Researchers Compare Intravitreal Implants for Non-Infectious Posterior Uveitis
There were no significant differences between dexamethasone and fluocinolone acetonide intravitreal implants in controlling inflammation; however, the latter is considered more difficult to use.
Could Dapagliflozin Treat Diabetic Retinopathy?
A discussion with an investigator on how the SGLT-2 inhibitor may help affected patients.
Data Supports Fluocinolone Acetonide Micro Implant Efficacy for Chronic DME
Up to 77% of patients maintained or improved best-corrected visual acuity at 12 month post-injection.
Missed Ophthalmology Appointments More Likely in Minority Populations
Hispanic and Black patients with chronic eye diseases had higher odds of missing out on appointments.
Study Offers Insight into Post-Intravitreal Injection Urgent Visits
Investigators report a low incidence rate of unscheduled or urgent visits within 7 days of injection.
Anti-VEGF Reduces Risk of Proliferative Diabetic Retinopathy Progression
A discussion on the uncovered benefits in risk reduction observed in patients with severe NDPR.
Addressing Frequent Cardiovascular Risk Factors in Visually Impaired Patients
CDC data suggest ophthalmic patients are significantly more likely to present with a heart disease-driving condition or habit. How could preventive care improve?
What Influences Diabetic Macular Edema Resolution with Anti-VEGF?
An assessment of VISTA and VIVID patient data uncovered surprising risk factors associated with aflibercept success or failure in DME resolution.
Investigators Explore the Impact of COVID-19 Lockdowns on Ocular Therapies
Patients with nAMD, DME, and RVO received fewer intravitreal injections between pre- and post-lockdown periods.